Article2018-02-06T17:27:34+00:00

Neumann Discusses Cures Act and New FDA Draft Guidance on Communication

In his latest Health Affairs blog posting, PHE Scientific Advisor Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payors and formulary committees about the real-world impacts of their products.

To read Dr. Neumann’s blog, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK